{"id":"https://openalex.org/W7214981007","doi":"https://doi.org/10.3390/pharma5040046","title":"Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess","display_name":"Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess","publication_year":2026,"publication_date":"2026-11-02","ids":{"openalex":"https://openalex.org/W7214981007","doi":"https://doi.org/10.3390/pharma5040046"},"language":"en","primary_location":{"id":"doi:10.3390/pharma5040046","doi":"https://doi.org/10.3390/pharma5040046","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharma5040046","pdf_url":null,"source":{"id":"https://openalex.org/S4210191524","display_name":"Pharmacoepidemiology","issn_l":"2813-0618","issn":["2813-0618"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3390/pharma5040046","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5153651941","display_name":"Esteban Zavaleta-Monestel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Esteban Zavaleta-Monestel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117230174","display_name":"Jeaustin Mora-Jim\u00e9nez","orcid":"https://orcid.org/0009-0001-0543-2262","observed_orcids":["https://orcid.org/0009-0001-0543-2262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeaustin Mora-Jim\u00e9nez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015348609","display_name":"Jorge Arturo Villalobos-Madr\u00edz","orcid":"https://orcid.org/0009-0005-7404-0106","observed_orcids":["https://orcid.org/0009-0005-7404-0106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jorge Arturo Villalobos-Madriz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138777626","display_name":"Kevin Tencio-Morales","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Tencio-Morales","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138820518","display_name":"Brandon Enr\u00edquez-Guti\u00e9rrez","orcid":"https://orcid.org/0009-0001-1799-3710","observed_orcids":["https://orcid.org/0009-0001-1799-3710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandon Enr\u00edquez-Guti\u00e9rrez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153595138","display_name":"Jos\u00e9 Andr\u00e9s Castro Gamboa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Andr\u00e9s Castro Gamboa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5070446816","display_name":"Sebasti\u00e1n Arguedas\u2010Chac\u00f3n","orcid":"https://orcid.org/0000-0001-8547-7745","observed_orcids":["https://orcid.org/0000-0001-8547-7745"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sebasti\u00e1n Arguedas-Chac\u00f3n","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5153651941"],"corresponding_institution_ids":[],"apc_list":{"value":1000,"currency":"CHF","value_usd":1207},"apc_paid":{"value":1000,"currency":"CHF","value_usd":1207},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.7259243,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"5","issue":"4","first_page":"46","last_page":"46"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.7383000254631042,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.7383000254631042,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.24690000712871552,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11638","display_name":"Cardiac tumors and thrombi","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antineoplastic-therapy","display_name":"antineoplastic therapy","score":0.8209999799728394},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.8389999866485596},{"id":"https://openalex.org/keywords/adverse-cardiac-events","display_name":"adverse cardiac events","score":0.9079999923706055},{"id":"https://openalex.org/keywords/anthracyclines","display_name":"anthracyclines","score":0.8619999885559082},{"id":"https://openalex.org/keywords/anti-her2-agents","display_name":"anti-HER2 agents","score":0.9710000157356262},{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.949999988079071},{"id":"https://openalex.org/keywords/disproportionality-analysis","display_name":"disproportionality analysis","score":0.8270000219345093},{"id":"https://openalex.org/keywords/reporting-odds-ratio","display_name":"reporting odds ratio","score":0.7620000243186951},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.8100000023841858},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.8730000257492065},{"id":"https://openalex.org/keywords/cardiomyopathy","display_name":"cardiomyopathy","score":0.9480000138282776},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8429999947547913}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.880299985408783},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7649000287055969},{"id":"https://openalex.org/C199475168","wikidata":"https://www.wikidata.org/wiki/Q1539689","display_name":"MedDRA","level":4,"score":0.6789000034332275},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.5210000276565552},{"id":"https://openalex.org/C2778233292","wikidata":"https://www.wikidata.org/wiki/Q2118956","display_name":"Cardiotoxicity","level":3,"score":0.5139999985694885},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4830000102519989},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.4634999930858612},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4560000002384186},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4560000002384186},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44620001316070557},{"id":"https://openalex.org/C2909231917","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Antineoplastic Drugs","level":2,"score":0.4291999936103821},{"id":"https://openalex.org/C2778797674","wikidata":"https://www.wikidata.org/wiki/Q847583","display_name":"Cardiomyopathy","level":3,"score":0.4244000017642975},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.41200000047683716},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.3977999985218048},{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.3824000060558319},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3310999870300293},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3077000081539154},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.2996000051498413},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.2824999988079071},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.27709999680519104},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.26249998807907104},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.2623000144958496},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2612999975681305},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2515000104904175},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.25099998712539673},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.25060001015663147}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3390/pharma5040046","doi":"https://doi.org/10.3390/pharma5040046","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharma5040046","pdf_url":null,"source":{"id":"https://openalex.org/S4210191524","display_name":"Pharmacoepidemiology","issn_l":"2813-0618","issn":["2813-0618"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology","raw_type":"journal-article"},{"id":"doi:10.20944/preprints202606.1291.v2","doi":"https://doi.org/10.20944/preprints202606.1291.v2","is_oa":true,"landing_page_url":"https://doi.org/10.20944/preprints202606.1291.v2","pdf_url":null,"source":{"id":"https://openalex.org/S6309402219","display_name":"Preprints.org","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.3390/pharma5040046","doi":"https://doi.org/10.3390/pharma5040046","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharma5040046","pdf_url":null,"source":{"id":"https://openalex.org/S4210191524","display_name":"Pharmacoepidemiology","issn_l":"2813-0618","issn":["2813-0618"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1684140257","https://openalex.org/W2121785313","https://openalex.org/W2140182328","https://openalex.org/W2158377392","https://openalex.org/W2164363535","https://openalex.org/W2205841570","https://openalex.org/W2263282442","https://openalex.org/W2514340051","https://openalex.org/W2591131474","https://openalex.org/W2617390885","https://openalex.org/W2742729000","https://openalex.org/W2793069147","https://openalex.org/W2921772931","https://openalex.org/W2999122927","https://openalex.org/W3024311355","https://openalex.org/W4212783034","https://openalex.org/W4293217929","https://openalex.org/W4295242229","https://openalex.org/W4316881713","https://openalex.org/W4317485907","https://openalex.org/W4318482201","https://openalex.org/W4387145510","https://openalex.org/W4394739014","https://openalex.org/W4394859740","https://openalex.org/W4395446529","https://openalex.org/W4396696202","https://openalex.org/W4400052486","https://openalex.org/W4401056091","https://openalex.org/W4404766249","https://openalex.org/W4405088545","https://openalex.org/W4407853601","https://openalex.org/W4409781897","https://openalex.org/W4414679340","https://openalex.org/W7119800677","https://openalex.org/W7133216968"],"related_works":["https://openalex.org/W7165001598","https://openalex.org/W4417263445","https://openalex.org/W4414618794","https://openalex.org/W4409781897","https://openalex.org/W7211882910","https://openalex.org/W2215245712","https://openalex.org/W7204922324","https://openalex.org/W4390122317","https://openalex.org/W3031051371","https://openalex.org/W7161556724"],"abstract_inverted_index":{"Background/Objectives:":[0],"Antineoplastic":[1],"therapies":[2,281],"have":[3,18],"improved":[4],"cancer":[5],"survival":[6],"but":[7],"remain":[8,44,340],"a":[9,63,127,136,205,259,283],"major":[10],"source":[11],"of":[12,101,198,268,312],"treatment-related":[13],"cardiotoxicity.":[14],"Previous":[15],"pharmacovigilance":[16,71,315],"studies":[17],"largely":[19],"focused":[20],"on":[21,41],"drug-specific":[22,151,155],"cardiac":[23,51,110,146,199,244],"signals":[24,290],"or":[25,335],"individual":[26],"therapeutic":[27,97],"pathways,":[28],"whereas":[29],"cross-class":[30],"differences":[31],"in":[32],"cardiovascular":[33,296],"reporting":[34,53,206,223,250,286,326,343],"across":[35,55],"MedDRA":[36],"categories":[37],"and":[38,59,109,169,216,229,231,279,308,321,347],"their":[39],"impact":[40],"disproportionality":[42,173],"estimates":[43],"less":[45],"well":[46],"characterized.":[47],"We":[48],"therefore":[49],"compared":[50],"adverse-event":[52],"patterns":[54,256,327],"anthracyclines,":[56],"anti-HER2":[57],"agents,":[58],"anti-VEGF":[60,280],"agents":[61,92,161,220,263],"within":[62,224],"restricted":[64,128],"antineoplastic":[65,91,129,252],"comparator":[66,130],"cohort.":[67,131],"Methods:":[68],"A":[69],"retrospective":[70],"study":[72],"was":[73],"conducted":[74],"using":[75,126],"aggregated":[76],"ICSR":[77],"data":[78,339],"from":[79],"VigiBase":[80],"accessed":[81],"through":[82],"the":[83,163,170,183,195,225,240,265,275,306,309],"public":[84],"VigiAccess":[85,152],"interface":[86],"(March":[87],"23,":[88],"2026).":[89],"Eight":[90],"were":[93,114,124,133,158],"grouped":[94],"into":[95],"three":[96],"classes.":[98],"Descriptive":[99],"analyses":[100],"demographic":[102],"characteristics,":[103],"System":[104],"Organ":[105],"Class":[106],"(SOC)":[107],"distributions,":[108],"Preferred":[111,211],"Terms":[112],"(PT)":[113],"performed.":[115],"Reporting":[116],"Odds":[117],"Ratios":[118],"(ROR)":[119],"with":[120,142,180,204,236,299],"95%":[121,138,177,189],"confidence":[122],"intervals":[123],"calculated":[125],"Signals":[132],"defined":[134],"as":[135,325],"lower":[137],"CI":[139],"bound":[140],">1":[141],"at":[143],"least":[144],"five":[145],"reports.":[147],"Results:":[148],"Across":[149],"eight":[150],"queries,":[153],"389,068":[154],"report":[156],"observations":[157],"analyzed.":[159],"Anti-HER2":[160,262],"showed":[162,221,264],"highest":[164,266],"proportional":[165],"cardiac-reporting":[166],"burden":[167],"(10.43%)":[168],"strongest":[171,184],"class-level":[172],"signal":[174],"(ROR":[175,187],"2.04;":[176],"CI:":[178,190],"1.99\u20132.10),":[179],"trastuzumab":[181],"showing":[182],"individual-drug":[185],"estimate":[186],"2.22;":[188],"2.16\u20132.29).":[191],"Anthracyclines":[192],"accounted":[193],"for":[194,251],"largest":[196],"number":[197],"reports":[200,269],"(n":[201],"=":[202],"11,273),":[203],"pattern":[207],"dominated":[208],"by":[209,214],"myocardial-dysfunction":[210],"Terms,":[212],"led":[213],"cardiomyopathy":[215],"heart":[217],"failure.":[218],"Anti-VEGF":[219],"greater":[222],"Vascular":[226],"disorders":[227,233],"(10.86%)":[228],"Renal":[230],"urinary":[232],"(6.08%)":[234],"SOCs,":[235],"myocardial":[237],"infarction":[238],"among":[239],"most":[241],"frequently":[242],"reported":[243],"PTs.":[245],"Conclusions:":[246],"Cardiac":[247,272],"adverse":[248],"event":[249],"therapy":[253],"follows":[254],"class-specific":[255,295],"rather":[257,328],"than":[258,329],"uniform":[260],"profile.":[261,287],"proportion":[267],"classified":[270],"under":[271],"disorders,":[273],"anthracyclines":[274],"greatest":[276],"absolute":[277],"volume,":[278],"exhibited":[282],"distinct":[284],"vascular\u2013ischemic":[285],"These":[288,317],"reporting-based":[289],"may":[291],"support":[292],"hypotheses":[293],"regarding":[294],"surveillance":[297],"consistent":[298],"established":[300],"cardio-oncology":[301],"guidance,":[302],"while":[303],"highlighting":[304],"both":[305],"value":[307],"inherent":[310],"limitations":[311],"global":[313],"spontaneous-reporting":[314],"data.":[316],"findings":[318],"are":[319],"hypothesis-generating":[320],"should":[322],"be":[323],"interpreted":[324],"incidence":[330],"estimates,":[331],"comparative":[332],"clinical":[333,349],"risks,":[334],"causal":[336],"effects.":[337],"Spontaneous-reporting":[338],"susceptible":[341],"to":[342],"bias,":[344],"unmeasured":[345],"confounding,":[346],"incomplete":[348],"information.":[350]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-01T00:00:00"}